Apolipoprotein B/apolipoprotein A-I ratio in relation to various definitions of metabolic syndrome among Saudi patients with type 2 diabetes mellitus

Saudi Medical Journal

Volumn 29, Issue 6, 2008, Pages 821-825

  Alfadda, Assim A ^a   Al Daghri, Nasser M ^b   Malabu, Usman H ^c  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c TOWNSVILLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; SAUDI ARABIA; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SAUDI ARABIA;

EID: 49149100802     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. Cholesterol reduction yields clinical benefits: Meta-analysis including recent trials. Clin Ther 2007; 29: 778-794.
2. Gonzalez-Clemente JM, Palma S, Arroyo J, Vilardell C, Caixas A, Gimenez-Palop O, et al. [Is diabetes mellitus a coronary heart disease equivalent? Results of a meta-analysis of prospective studies]. Rev Esp Cardiol 2007; 60: 1167-1176.
3. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008; 197: 392-399.
4. Hong Y, Jin X, Mo J, Lin HM, Duan Y, Pu M, et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality-results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med 2007; 262: 113-122.
5. Asia Pacific Cohort Studies Collaboration. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia 2007; 50: 2289-2297.
6. Christen A, Efstathiadou Z, Laspa E, Johnston DG, Godsland IF. Rate of change and instability in body mass index, insulin resistance, and lipid metabolism as predictors of atherosclerosis vascular disease. J Clin Endocrinol Metab 2007; 92: 3780-3787.
7. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, et al. Beyond low-density lipoprotein cholesterol: Defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 2007; 50: 1735-1741.
8. Sniderman AD. Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: Alternatives and surrogates versus the real thing. Diabetes Care 2003; 26: 2207-2208.
9. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 225: 188-205.
10. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance I, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93: 159-64.
11. Kim BJ, Hwang ST, Sung KC, Kim BS, Kang JH, Lee MH, et al. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 2005; 51: 2257-2263.
12. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006; 26: 406-410.
13. Sierra-Johnson J, Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Gami AS, et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006; 98; 1369-1373.
14. Fridewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
15. World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications; Report of a WHO Consultation. Part I: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland; World Health Organization; 1999.
16. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA 2001; 285: 2486-2497.
17. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation, Diabet Med 2006; 23: 469-48O.
18. Relimpio F, Losada F, Pumar A, Mangas MA, Morales F, Astorga R. Relationships of apolipoprotein B(100) with the metabolic syndrome in Type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 57: 199-207.
19. Wallenfeldt K, Bokemark. L, Wikstrand J, Hulthe J, Fagerberg B. B, Api.-tilimprowirt BlalvAilmlprotein Ai-I 1.n rektinn to dic Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media tl.-tickncu dlirirtg 3 ycoxs in midific-ig.c.4 mcn. Srmke 24-44; 35, thickness during 3 years in middle-aged men. Stroke 2004; 35: 2248-2252.
20. Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glymic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55), Diabetes Care 2001; 24: 1167- 1174.
21. DeFronzo RA, Ferrannini E, Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
22. Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of waist circumference in the definition of metabolic syndrome: Prospective analyses of mortality in men. Diabetes Care 2006; 29: 404-409.
23. Pascot A, Despres JP, Lemieux I, Bergeron J, Nadeau A. Pru d'homme D, et al, Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 2000; 43: 1126- 1135.
24. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A, et al. ApoB/apoA-I ratio: An independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J 2007; 28; 2637-2643.